Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)
National Institutes of Health · Department of Health and Human Services
At a glance
Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed) is an open federal cooperative agreement opportunity from the National Institutes of Health (Department of Health and Human Services). Applications are due October 8, 2027. Applicant types listed as eligible include state governments, county governments, city or township governments, special district governments, independent school districts and 10 more. Cost sharing is not required. It is funded under Assistance Listing 93.393 (Cancer Cause and Prevention Research).
Summary assembled from the official notice's fields. The official notice governs.
Key facts
- Posted
- Nov 21, 2024
- Close date
- Oct 8, 2027
- Archive date
- Nov 13, 2027
- Award floor
- Not specified
- Award ceiling
- Not specified
- Est. total funding
- Not specified
- Expected awards
- Not specified
- Cost sharing
- Not required
- Funding instrument
- Cooperative Agreement
- Opportunity category
- Discretionary
Who can apply
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public colleges & universities
- Federally recognized tribal governments
- Public & Indian housing authorities
- Native American tribal organizations
- 501(c)(3) nonprofits
- Nonprofits without 501(c)(3) status
- Private colleges & universities
- For-profit organizations (not small businesses)
- Small businesses
- Others (see notice)
Additional information on eligibility (from the notice)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Based on the published notice. Review the official notice for complete eligibility requirements.
What it funds
Official synopsis as published by the agency, formatted for readability.
This Funding Opportunity Announcement (FOA) encourages the submission of applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial. The PLCO Biorepository offers high-quality, prospectively collected, serial pre-diagnostic blood samples from the PLCO screened arm participants, and a onetime collection of buccal cells from the control arm participants. Available data associated with the biospecimens includes demographic, diet, lifestyle, smoking, screening results, and clinical data. This FOA supports a wide range of cancer research including, but not limited to, biochemical and genetic analyses of cancer risk, as well as discovery and validation of early detection biomarkers. The proposed research project must involve use of PLCO biospecimens; additionally, it should also take advantage of the unique characteristics of the PLCO biospecimens. Research projects that do not involve the use of PLCO biospecimens will not be supported under this FOA.
Assistance Listing
What is an ALN?Reported obligations under ALN 93.393
Historical data · not a predictionAgency contact (as published)
National Institutes of Health
grantsinfo@nih.gov
301-402-2541
Quick answers
When is the deadline for this opportunity?
According to the official notice, applications are due October 8, 2027. Confirm the deadline and submission time on Grants.gov before applying.
Who is eligible to apply for this opportunity?
The official notice lists these applicant types as eligible: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public colleges & universities, Federally recognized tribal governments, Public & Indian housing authorities, Native American tribal organizations, 501(c)(3) nonprofits, Nonprofits without 501(c)(3) status, Private colleges & universities and 3 more. Additional restrictions may apply; review the full notice.
How do I apply for this opportunity?
Applications are submitted through the official source, not through GrantsJunction. Open the official notice on Grants.gov (opportunity PAR-25-248), and review the full announcement and application package. Organizations applying through Grants.gov generally need an active SAM.gov registration and a Grants.gov account, which can take several weeks to set up.
Related open opportunities
Matched on shared Assistance Listings, agency, categories and eligible applicant types.
Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)
National Institutes of Health- Award range
- Up to $350K
- Closes
- Nov 6, 2026
- Who can apply
- State governments, County governments, City or township governments and 12 more
Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)
National Institutes of Health- Award range
- Up to $200K
- Closes
- Nov 17, 2026
- Who can apply
- State governments, County governments, City or township governments and 12 more
Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Required)
National Institutes of Health- Award range
- Up to $375K
- Closes
- Jan 7, 2027
- Who can apply
- Public colleges & universities, Private colleges & universities and Others (see notice)
Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)
National Institutes of Health- Award range
- Amount not specified
- Closes
- Jan 7, 2027
- Who can apply
- State governments, County governments, City or township governments and 12 more
Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
National Institutes of Health- Award range
- Amount not specified
- Closes
- Jan 7, 2027
- Who can apply
- State governments, County governments, City or township governments and 12 more
Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)
National Institutes of Health- Award range
- Amount not specified
- Closes
- Jan 7, 2027
- Who can apply
- State governments, County governments, City or township governments and 12 more